The worldwide distribution agreement expands Oxford's existing product and service portfolio, streamlining workflows for current customers, the company said.
The UN Convention on Biodiversity has rejected a moratorium on gene drives, Nature News says.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
The President's Council of Advisors on Science and Technology urges the adoption of a biodefense strategy, Tech Review reports.
The company said it would use the funding to continue licensing its DNA design technology in the cell and gene therapy markets.
The DNA foundries have been funded through an £18 million ($23.5 million) investment from the BBSRC and should all be fully operational by next year.
In Science this week: effort to reduce E. coli genome, and more.
The Scientist traces the career path of the J. Craig Venter Institute's Clyde Hutchinson.
The firm is developing protein therapies incorporating synthetic amino acids coded for by "unnatural" base pairs developed at The Scripps Research Institute.
The company said it will use the proceeds to fund its growth into new markets, and to build its next-generation automated foundry.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.